Acadia snags Amgen, Horizon vet to direct R&D; Samantha Truex steps down as Upstream Bio CEO
05 Apr 2024
Executive ChangeAcquisitionDrug Approval
→ Just a few weeks after Amgen touted its efforts in rare disease, EVP of R&D in that therapeutic area is departing to lead R&D at Acadia Pharmaceuticals. Elizabeth Thompson will steer research and development at the neuroscience drugmaker after serving in key roles on the pre- and post-marketing work of Horizon’s medicines. She contributed to Tepezza, Krystexxa and Uplizna, among other drugs, during her time at the Chicago and Ireland biopharma, which Amgen bought last year for nearly $28 billion. She joins Acadia about 13 months after it secured its second FDA approval. Her career includes a prior 10-year tenure at Amgen and roles at InterMune, Raptor and AbbVie.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.